Unlike nuclear-targeted anthracyclines, the extranucleartargeted doxorubicin congener, N-benzyladriamycin-14-valerate (AD 198), does not interfere with normal topoisomerase II activity, but binds to the C1b regulatory domain of conventional and novel isoforms of protein kinase C (PKC). The resulting interaction leads to enzyme activation and rapid apoptosis in a variety of mammalian cell lines through a pathway involving mitochondrial events such as membrane depolarization (Dc 
Unlike nuclear-targeted anthracyclines, the extranucleartargeted doxorubicin congener, N-benzyladriamycin-14-valerate (AD 198), does not interfere with normal topoisomerase II activity, but binds to the C1b regulatory domain of conventional and novel isoforms of protein kinase C (PKC). The resulting interaction leads to enzyme activation and rapid apoptosis in a variety of mammalian cell lines through a pathway involving mitochondrial events such as membrane depolarization (Dc m ) and cytochrome c release. Unlike other triggers of apoptosis, AD 198-mediated apoptosis is unimpeded by the expression of Bcl-2 and Bcl-X L . We have further examined AD 198-induced apoptosis in 32D. 
Introduction
Changes in mitochondrial structure and function play a critical role in the potentiation of apoptotic signaling initiated by multiple stimuli [1] . Interaction of mitochondria with either pro-apoptotic members of the Bcl-2 family of proteins [2] , caspases [3] or cytotoxic compounds directly, such as betulinic acid [4] , can induce the formation of large multi-component pore complexes [permeability transition pore complex (PTPC)] whose assembly and activity accompany the loss of mitochondrial membrane potential (Dc m ), and the release of cytochrome c, apoptosis-inducing factor (AIF), Smac/ DIABLO and Ca 2 + from within the mitochondria. Cytochrome c and AIF, in turn, facilitate the proteolytic activation of caspases-6, -9 and -3, and nuclear endonucleases [5] , while Smac/DIABLO facilitates caspase activation by inhibiting inhibitors of apoptosis proteins [6] . The PTPC is a multimeric protein complex formed by the association of the voltage-dependent anion channel (VDAC) in the outer membrane with the adenine nucleotide translocator (ANT) in the inner membrane along with other mitochondrial proteins including cyclophilin D (CyP-D), benzodiazepine receptor and hexokinase [1] . Expression of the pro-apoptotic members of the Bcl-2 family of proteins (e.g. Bax, Bad, Bid, Bak and Bcl-X S ), alone, is sufficient to promote cytochrome c release and apoptosis [7] . Bax, for example, is reported to insert into the outer mitochondrial membrane, and promote PTPC formation and opening, leading to Dc m [8] . Critical to these mitochondrial apoptotic events is the flux of Ca 2 + across mitochondrial membranes. Ca 2 + uptake from the extracellular stores and released endoplasmic reticulum (ER) stores can lead to Ca 2 + overload within mitochondria and induce the association of CyP-D with ANT, resulting in PTPC opening [9] . The influx of Ca 2 + may proceed through several routes: influx through the PTPC itself [9] , through Ca 2 + uniporters in the inner membrane [10] , through non-selective cation channels [11] or through a mechanism termed rapid mode of Ca 2 + uptake, so far identified in hepatocytes and cardiomyocytes [12] . Consequently, pro-apoptotic mitochondrial events are inhibited by: expression of anti-apoptotic Bcl-2 proteins that either close the VDAC protein of the PTPC, heterodimerize and inhibit the actions of Bax and other pro-apoptotic Bcl-2 proteins or block Ca 2 + release from the ER [2] ; cyclosporin A (CsA) and bongkrekic acid, which bind CyP-D in the PTPC to block opening [1] ; or Ca 2 + chelators that prevent mitochondrial Ca 2 + influx [11] . Thus, elevated expression of anti-apoptotic Bcl-2 proteins or pre-treatment of cells with these agents will block the mitochondrial-mediated activation of caspases required for the effector stage of apoptosis and preserve cell viability.
Mitochondrial involvement in apoptotic signaling is also mediated by members of the C family of Ser/Thr protein kinases (PKC) [13] . Pro-apoptotic activity is observed with PKC-a [14] , PKC-d [15] [16] [17] and PKC-e [17] . In particular, PKC-d activity is associated with apoptosis induced by chemotherapeutic agents, radiation, oxidative stress, death receptor ligands and phorbol esters [18] . The pro-apoptotic effects of PKC-d are reported to be both a consequence of caspase-3-mediated cleavage of the catalytic domain from the regulatory regions [19] , as well as the activation of PKC-d holoenzyme [16] . Under both circumstances, PKC-d activity coincides with the translocation of PKC-d to the mitochondrial membrane [19] [20] [21] . The target molecules of activated PKC-d are not fully identified, but are reported to include: c-Abl, resulting in Dc m and necrotic-like cell death [22] ; p73b tumor-suppressor protein, phosphorylated by the caspasegenerated catalytic fragment [23] ; lamin, whose phosphorylation results in nuclear lamina disassembly during apoptosis [24] ; the mitochondrial enzyme phospholipid scramblase 3 (PLS3), whose phosphorylation is associated with mitochondrial-dependent apoptosis [25] ; and DNAdependent protein kinase [26] . PKC-d-mediated induction of apoptosis through mitochondrial association is blocked by the expression of anti-apoptotic Bcl-2 proteins [16] and renders those cells resistant to apoptosis triggered by various stimuli, including anti-tumor anthracyclines [27] .
In previous studies we have shown that the novel, extranuclear-targeted anthracyclines N-benzyladriamycin-14-valerate (AD 198) and N-benzyladriamycin-14-pivalate (AD 445) trigger rapid apoptosis in a variety of cell lines in a manner that circumvents multiple mechanisms of drug resistance, including overexpression of the multidrug transporters P-glycoprotein and MRP [28] [29] , decreased topoisomerase II activity [30] , p53 dysfunction [31] , NF-kB activation [32] , and the expression of Bcl-2 and Bcl-X L [31] [32] . Unlike nucleartargeted anthracyclines such as doxorubicin (DOX) or epirubicin, AD 198 and AD 445 do not inflict DNA damage through inhibition of topoisomerase II activity [28, 30] . Rather, AD 198 and AD 445 bind to the C1b regulatory domain of conventional and novel PKC isozymes in a manner that competitively inhibits phorbol ester binding, but nevertheless activates PKC [31, 33, 34] . In 32D.3 murine myeloid cells, AD 198 and AD 445 rapidly trigger mitochondrial membrane depolarization and cytochrome c release within 1 h of treatment. Expression of transfected human Bcl-2 or Bcl-X L has no effect in inhibiting AD 198-and AD 445-induced apoptosis, but inhibits DOX-mediated apoptosis. However, the PKC-d-selective inhibitor, rottlerin, specifically inhibits AD 198 and AD 445 apoptosis, but has no effect on the cytotoxicity of DOX or N-benzyladriamycin (AD 288) -a topoisomerase II catalytic inhibitor, and the principal cellular biotransformation product of AD 198 and AD 445 [35] . In an effort to determine how AD 198 circumvents the anti-apoptotic effects of Bcl-2, we examined the mechanism by which AD 198 triggers Dc m and cytochrome c release. We found that both events are triggered independently of PTPC activity and Ca 2 + flux, but require the activation of PKC-d holoenzyme rather than the cleaved catalytic subunit.
Materials and methods

Cell culture and reagents
Interleukin (IL)-3-dependent 32D.3 murine myeloid cell lines, transfected with either empty SFFV expression vector [36] or SFFV-Bcl-2 (32D.3/Bcl-2), (generous gift of Dr John Cleveland, St Jude Hospital, Memphis, Tennessee, USA) described previously [37] , were maintained in RPMI 1640 medium with L-glutamine (Atlanta Biologicals, Norcross, Georgia, USA) supplemented with 10% FBS (Atlanta Biologicals) and 40 U/ml IL-3 (Sigma, St Louis, Missouri, USA) [38] . DOX was obtained from Sigma, while AD 288 and AD 198 hydrochloride salts were prepared in this laboratory according to previously described procedures [30] . Rottlerin, Z-VAD-FMK, CsA, betulinic acid and BAPTA-AM were obtained from Calbiochem (La Jolla, California, USA). All drugs were dissolved in DMSO. The final maximum DMSO concentration used in drug treatments (2% for 5 h) is not cytotoxic. washed twice in warm PBS and prepared for staining with 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolyl carbocyanin iodide (DePsipher; Trevigen, Gaithersburg, Maryland, USA) according to the manufacturer's instructions. Cellular red fluorescence was observed microscopically (Olympus model BX60) using a filter above 620 nm.
Immunoblot analysis of cytochrome c release from mitochondria
For cytochrome c release into cytosol, cells were treated with drug as described above. After incubation in AD 198 for the times indicated, cells were washed in cold PBS, resuspended in mitochondrial isolation buffer (250 mmol/l sucrose, 20 mmol/l HEPES-KO 4 , pH 7.4, 1.5 mmol/l MgCl 2 , 10 mmol/l KCl and 1 mmol/l EDTA, with 1 mmol/l PMSF, 20 mmol/l leupeptin, 50 mg/ml pepstatin A, 50 mg/ml aprotonin and 2 mmol/l DTT) and incubated on ice for 20 min. Cells were lysed with a Dounce homogenizer and the lysate was subjected to centrifugation at 14 200 g for 15 min at 41C. The resulting supernatant containing the cytosolic fraction was lyophilized and then suspended in RIPA buffer (50 mmol/l TrisHCl, pH 8.0, 150 mmol/l NaCl, 0.1% SDS, 1% NP-40 and 0.5% sodium deoxycholate). Following protein determination of the samples, 100 mg of protein was resolved by SDS-PAGE in 15% polyacrylamide. Immunoblot analysis was performed as described previously [31] using an anticytochrome c antibody (BD Biosciences, San Diego, California, USA).
Cell viability determination 32D.3 cells, at a density of 5 Â 10 5 /ml, were exposed to the IC 90 concentrations (drug concentration required to kill 90% of 32D.3 cells 72 h after a 1-h drug treatment; 5 mmol/l) of AD 198 and AD 288 in complete medium for 1 h at 371C in a 5% CO 2 humidified environment. Control cells were treated with 1% DMSO for 1 h. Following drug treatment, cells were washed twice with PBS and incubated further in drug-free media. At the times indicated, 75-ml aliquots of cell suspension were combined with 25 ml Trypan blue (Life Technologies, Rockville, Maryland, USA) and assayed microscopically for cellular dye exclusion.
Transdominant-negative PKC-d vector transfection and kinase activity assay 32D.3 cells were stably transfected by electroporation with either non-recombinant pCEV expression vector or PKC-dK376R transdominant-negative PKC-d [39] , both a kind gift of Dr Weiqun Li (Georgetown University). Transfected clones were selected by limited dilution cloning, in which cells were diluted to one cell per 5-mm cell culture well, and assessed for changes in PKC-d activity by measuring kinase activity of calcium-independent PKC towards the PKC pseudo-substrate peptide (Upstate Biotechnology, Lake Placid, New York, USA [33, 34] ). Kinase-specific activity was calculated by subtracting basal activity from total catalytic activity and expressed as fmol/phosphate/min/mg [34] .
Results
Blocking PCK-d activity inhibits AD 198-induced cell kill
As we have shown previously, AD 198 induces rapid apoptosis in 32D.3 murine myeloid cells, with less than 20% of the initial cell population remaining viable within 12 h after a 1-h exposure to 5 mmol/l AD 198 [31] (Fig. 1a) . The PKC inhibitor, rottlerin, at a concentration that selectively inhibits PKC-d activity (10 mmol/l) [40] , decreases cell sensitivity to AD 198, increasing cell viability to 80% after 12 h post-drug exposure and from 8 to 50% after 24 h. Previous reports have suggested, however, that rottlerin may have mitochondrial effects that occur independently of PKC-d [41] . In order to confirm that specific inhibition of PKC-d activity decreases 32D.3 sensitivity to AD 198, we transfected 32D.3 cells with the PKC-dK376R transdominant-negative PKC-d expression vector. A representative clone, TDN-4, exhibits Ca + -independent PKC activity that is reduced by 42% relative to control cells transfected with non-recombinant vector (pCEV-2). Reduced PKC activity corresponds to a delay in 50% cell kill from 8 to 18 h after AD 198 treatment. In contrast, reduced PKC activity had no significant effect on AD 288 cytotoxicity (data not shown). Together with previous studies using an array of PKC inhibitors, these results indicate that PKC-d activity is required for AD 198-mediated cell kill. We have previously demonstrated that the mitochondria of untreated 32D.3 cells contain PKC-d [31] , suggesting that mitochondria are a likely target for AD 198. These results indicate that AD 198 activates PKC-d holoenzyme to achieve mitochondrial depolarization. AD 198-mediated mitochondrial depolarization is not blocked by the expression of Bcl-2 or Bcl-X L [31, 32] . Since one inhibitory function of the anti-apoptotic Bcl-2 proteins is prevention of PTPC formation and activation [1] , we further assessed the ability of AD 198 to trigger Dc m despite inhibition of PTPC activation (Fig. 2) . CsA has been shown to bind to CyP-D [42] , and inhibit both Dc m and cytochrome c release induced by a wide variety of stimuli [9, 43] . Treatment of 32D.3 cells with 5 mmol/l CsA for 4 h had no effect on Dc m (not shown). Betulinic acid, a novel anti-tumor agent that induces apoptosis through direct interaction with mitochondria [4] , induces Dc m in a manner that is inhibited by CsA treatment [1] , as shown by the preservation of punctate fluorescence. However, 5 mmol/l CsA does not inhibit AD 198-induced Dc m .
The release of cytochrome c often coincides with Dc m and is an essential component for caspase-3 activation [1] . AD 198 treatment of 32D.3 cells results in the rapid release of cytochrome, detectable by immunoblot analysis of cytosolic fractions after 2 h of drug exposure (Fig. 3a) . Combined treatment with 10 mmol/l rottlerin inhibits cytochrome c release. Five mmol/l CsA treatment in combination with AD 198, however, did not inhibit cytochrome c release. Further, increasing concentrations of CsA up to 15 mmol/l failed to inhibit cytochrome c release by AD 198 (Fig. 3b) . These results indicate that AD 198-mediated cytochrome c release requires PKC-d activation, but does not require PTPC formation and opening.
AD 198-induced mitochondrial depolarization is Ca 2 + -independent
The independence of AD 198-mediated Dc m and cytochrome c release from PTPC functional status suggests that Ca 2 + uptake may trigger Dc m through alternate mitochondrial transport [10] [11] [12] or does not play a role in AD 198-mediated mitochondrial responses. Consequently, intra-and extracellular Ca 2 + was chelated with BAPTA-AM and EGTA, respectively, prior to AD 198 treatment to determine whether AD 198-mediated cell kill is Ca 2 + dependent in 32D.3 cells (Fig. 4a) . The Ca 2 + ionophore A23187 induced greater than 90% cell kill within 1 h of treatment of 32D.3. BAPTA-AM/EGTA treatment, however, inhibited A23187 cytotoxicity, with less than 15% cell kill after 6 h beyond that observed with BAPTA-AM/EGTA alone, indicating effective Ca 2 + chelation. Under these conditions, the rate of AD 198-mediated cell kill was unaffected by Ca 2 + chelation. Further, BAPTA-AM/EGTA treatment also blocked cytochrome c release induced by A23187, but failed to block release by AD 198 or the closely related AD 445 (Fig. 4b) , suggesting that AD 198-induced apoptosis does not require cellular Ca 2 + flux.
Discussion
The results of our previous studies [31] and this present study indicate that AD 198 triggers mitochondrialdependent apoptosis in 32D.3 murine myeloid cells through activation of PKC-d holoenzyme. Further, the mechanism by which mitochondrial membranes undergo depolarization and promote cytochrome c release for subsequent involvement in caspase activation is not dependent upon PTPC formation or Ca 2 + flux and suggests a novel pathway for AD 198-induced apoptosis. PKC-d has been shown previously to be a potent mediator of apoptotic signaling, both as a holoenzyme [15, 16] and following caspase-mediated cleavage to yield a constitutively active catalytic subunit [44] [45] [46] . Further, the holoenzyme and cleaved catalytic fragment may coordinate their activities in a positive feedback loop mediated by caspase-3 action [18, 47] . While blockade of caspase-3-mediated PKC-d cleavage by Z-VAD-FMK inhibits latestage AD 198-mediated apoptosis, as monitored by Trypan blue staining [31] , the detection of both Dc m and cytochrome c release in the presence of Z-VAD-FMK indicates that PKC-d cleavage is not a requisite step for mitochondrial recruitment following AD 198 treatment, but, rather, PKC-d holoenzyme activity is sufficient and required. The requirement for PKC-d activity for AD 198-mediated apoptosis is supported by the ability of rottlerin to inhibit Dc m and cytochrome c release induced by AD 198, and, consequently, caspase-3-mediated apoptotic events such as DNA endonucleolytic activity, poly(ADP-ribose) polymerase cleavage and PKC-d cleavage [31] . The inability of rottlerin to inhibit Dc m triggered by AD 288 or apoptosis triggered by both AD 288 and DOX [31] suggests that mitochondrial recruitment by AD 288 and DOX does not require PKC-d holoenzyme activity. Both AD 288 and DOX inhibit topoisomerase II, albeit through different mechanisms [37] , and, consequently, trigger mitochondrial-dependent apoptosis through DNA damage/cell cycle arrest leading to p53-mediated expression of Bax. This would also be consistent with the ability of Bcl-2 and Bcl-X L expression to inhibit both AD 288-and DOX-mediated apoptosis [31, 32] . We have previously shown that AD 198, and the structurally and functionally similar AD 445, trigger apoptosis through a mechanism that is independent of DNA damage [32] . Consequently, AD 198 cytotoxicity is not affected by p53 dysfunction or Bcl-2/Bcl-X L expression [31, 32] . This latter observation poses the question of how AD 198 and, for that matter, AD 445 achieve PKC-d-mediated Dc m and cytochrome c release in the presence of Bcl-2. Phorbol ester-mediated Dc m and cytochrome c release through PKC-d holoenzyme activation is effectively blocked in LNCaP cells expressing Bcl-2 [16] , yet AD 198 and AD 445 cytotoxicity remains unaffected by Bcl-2 expression in myeloid cells, MCF-7 breast carcinoma cells [31] and LNCaP cells (unpublished results). Multiple anti-apoptotic mechanisms have been ascribed to Bcl-2, including heterodimerization with pro-apoptotic Bcl-2 family members, the mediation of Apaf-1 binding to the mitochondria membrane surface, inhibition of PTPC opening and inhibition of Ca 2 + release from the ER [15] . Our previous studies have indicated that Bcl-2 protein levels and phosphorylation status remain unchanged in 32D.3 cells following AD 198 treatment, suggesting that AD 198 bypasses the anti-apoptotic effects of Bcl-2 rather than inhibits Bcl-2 expression and activation [31] . Consistent with these findings is the ability of AD 198 to trigger Dc m and cytochrome c release in the presence of CsA, which binds to CyP-D, blocks PTPC activity and, consequently, inhibits apoptosis by a variety of genotoxic agents [1] . Flavopiridol, a cyclin-dependent kinase inhibitor, has, likewise, been reported to trigger Dc m and apoptosis in HeLa and SW2 cells in a manner independent of the effects of Bcl-2 and the PTPC inhibitor, bongkrekic acid [48] . This action has been ascribed either to the caspase-8-mediated activation of a mitochondrial-independent apoptotic pathway or the ability of flavopiridol to directly induce PTPC opening [48] . 32D.3 cells are FADD deficient [31] and do not induce apoptosis in a mitochondrial-independent pathway. Thus, it is likely that Dc m and cytochrome c release are a direct effect of AD 198 treatment rather than a secondary feedback effect. The sesquiterpene, helenalin, circumvents the anti-apoptotic effects of Bcl-2, yet still triggers mitochondrial-dependent apoptosis in Jurkat T cells [49] . Cytochrome c release following helenalin treatment is caspase independent, whereas Dc m appears to be caspase dependent. AD 198-induced Dc m and cytochrome c release, however, are both caspase independent, based upon the inability of Z-VAD-FMK to block either event. Our results suggest that AD 198 triggers mitochondrial apoptotic events through a novel pathway initiated by PKC-d holoenzyme activation. Since PKC-d is a Ca 2 + -independent isoform, the chelation of intracellular Ca 2 + would still permit PKC-d activation. Therefore, elucidation of the apoptotic signaling pathway activated by AD 198 requires the identification of mitochondrial PKC-d targets. One target of current interest is PLS3, a mitochondrial member of a family of enzymes capable of translocating phospholipids between inner and outer layers of a lipid bilayer membrane [50] . Increased expression of PLS3 has been shown previously to enhance UV radiation-induced apoptosis, while inhibition of PLS3 blocks UV and drug-induced apoptosis [50, 51] . PLS3 has also recently been shown to be a substrate for PKC-d; phorbol ester-mediated phosphorylation of PLS3 via PKC-d leads to mitochondrialdependent apoptosis in HEK293 and HeLa cells [50] . Further, we have recently demonstrated that in HeLa cells, AD 198 can trigger PLS3-mediated Dc m and apoptosis through PKC-d activation [52] . It is currently unknown whether PLS3-mediated apoptosis can occur independently of PTPC activation, Ca 2 + -flux and the anti-apoptotic effects of Bcl-2 or whether PLS3 activation is just one of several apoptotic pathways triggered by AD 198. While PLS3 can be activated in a Ca 2 + -dependent manner [50] , it has been reported recently that the anesthetic agent, dibucaine, triggers phosphotidylserine translocation, Dc m and apoptosis in platelets in the absence of Ca 2 + flux [53] . In summary, AD 198 is capable of triggering novel PKC-d holoenzyme-dependent apoptotic signaling that is independent of PTPC pore activity and Ca 2 + flux, and allowing circumvention of Bcl-2-mediated apoptotic inhibition.
